Accendra Health amends $150M receivables program

The program's $150 million size remains unchanged as its scheduled termination date extends to October 2029.

Available on EDGAR 11/02/2026 - 06:50 AM EST Accepted by SEC EDGAR 11/02/2026 - 06:50 AM EST Learn about SEC filing dates

Rhea-AI Filing Summary

Accendra Health, Inc. announced that its wholly owned subsidiaries Accendra Funding LLC and Byram Healthcare Centers, Inc. entered into a third amendment to the Receivables Purchase Agreement on October 29, 2026. The amendment extends the program’s Scheduled Termination Date to October 2029, with standard contingencies, while the program remains at $150 million. It also revises account control provisions and reporting obligations.

8-K Event Classification

3 items: 1.01, 7.01, 9.01

3 items

Item 1.01 Entry into a Material Definitive Agreement Business

The company signed a significant contract such as a merger agreement, credit facility, or major partnership.

Item 7.01 Regulation FD Disclosure Disclosure

Material non-public information disclosed under Regulation Fair Disclosure, often investor presentations or guidance.

Item 9.01 Financial Statements and Exhibits Exhibits

Financial statements, pro forma financial information, or exhibit attachments filed with this report.

Key Figures

Receivables Sale Program size: $150 million Scheduled Termination Date: October 2029 Amendment date: October 29, 2026

3 metrics

Receivables Sale Program size $150 million Size remains unchanged

Scheduled Termination Date October 2029 Extended by the amendment, with standard contingencies

Amendment date October 29, 2026 Date the subsidiaries entered into the third amendment

Key Terms

Scheduled Termination Date, Receivables Purchase Agreement, account control provisions, Servicer

4 terms

Scheduled Termination Date financial

"extends the Scheduled Termination Date until October 2029"

Receivables Purchase Agreement financial

"Third Amendment to the Amended & Restated Receivables Purchase Agreement"

A receivables purchase agreement is a contract where a company sells its outstanding invoices or amounts owed by customers to a buyer in exchange for immediate cash, usually at a discount. Investors care because it improves a company’s short‑term cash flow and can change reported assets, liabilities and risk exposure—like selling IOUs to get money now instead of waiting, which affects liquidity and the firm’s financial picture.

account control provisions financial

"revises account control provisions and reporting obligations"

Servicer financial

"Byram, as Servicer"

An entity that handles the day-to-day administration of loans or other financial assets on behalf of lenders or investors. Like a property manager for a building, a servicer collects payments, monitors accounts, enforces contract terms, handles missed payments and borrower communications; its efficiency and practices directly affect cash flow, credit quality and recovery prospects, so investors watch servicers for operational and performance risk.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

How large is Accendra Health's receivables sale program, and when is its scheduled termination date?

The Receivables Sale Program remains at $150 million, and its Scheduled Termination Date is extended to October 2029, with standard contingencies.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Understanding 8-K Material Events →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

0000075252false00000752522026-10-292026-10-29

​

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, DC 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): October 29, 2026

Accendra Health, Inc.

(Exact name of registrant as specified in its charter)

​

​ ​ ​	​	​
Virginia	001-09810	54-1701843
(State or other jurisdiction of	(Commission	(I.R.S. Employer
incorporation or organization)	File Number)	Identification No.)
​	​	​
4435 Waterfront Drive, Suite 300, Glen Allen, Virginia	​	23060
(Address of principal executive	​	​
offices)	​	(Zip Code)
​	​	​

​

Registrant’s telephone number, including area code (804) 277-4304

Securities registered pursuant to Section 12(b) of the Act:

​

​	​	​	​	​
Title of each class	​ ​ ​	Trading Symbol(s)	​ ​ ​	Name of each exchange on which registered
Common Stock, $2 par value per share	​	ACH	​	New York Stock Exchange

​

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2.below):

​

☐Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

​

☐Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

​

☐Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

​

☐Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

​

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company         ☐ If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.          ◻

​

​

​

Item 1.01 Entry into a Material Definitive Agreement.

Amendment to Receivables Securitization Program

On October 29, 2026, Accendra Funding LLC (“Accendra Funding”) and Byram Healthcare Centers, Inc. (“Byram”) each a wholly-owned subsidiary of Accendra Health, Inc., entered into the Third Amendment to the Amended & Restated Receivables Purchase Agreement (the “RPA Amendment”), which amends that certain Amended & Restated Receivables Purchase Agreement, dated as of December 31, 2025, as amended, by and among Accendra Funding, as Seller, Byram, as Servicer, the persons from time to time party thereto, as Purchasers, PNC Bank, National Association (“PNC”), as Administrative Agent, and PNC Capital Markets LLC, as Structuring Agent (the “Receivables Purchase Agreement”). The RPA Amendment extends the Scheduled Termination Date until October 2029, with standard contingencies, and revises account control provisions and reporting obligations.

The foregoing description of the RPA Amendment is a summary, and is qualified in its entirety by reference to the complete terms of the RPA Amendment, a copy of which will be filed as an exhibit to the Company’s Annual Report on Form 10-K for the fiscal year ended December 31, 2026.

PNC Bank, National Association and PNC Capital Markets LLC have various relationships with the Company and its subsidiaries involving the provision of financial services, including investment banking, commercial banking, advisory, cash management, custody and trust services, for which they have received customary fees, and may do so again in the future.

​

​

Item 7.01 Regulation FD Disclosure.

On November 2, 2026, the Company issued a press release related to the foregoing. The press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference.

​

The information in Exhibit 99.1 is being furnished pursuant to Item 7.01 of Form 8-K. In accordance with General Instruction B.2 of Form 8-K, the information in this Item 7.01, including Exhibit 99.1, shall not be deemed “filed” for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to the liability of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, except as shall be expressly set forth by specific reference in such a filing.

​

Item 9.01. Financial Statements and Exhibits.

​

(d) Exhibits.

The following materials are filed as exhibits to this Current Report on Form 8-K.

Exhibit Number		Description
99.1		Press Release of the Company, dated November 2, 2026 (furnished pursuant to Item 7.01).
104		Cover Page Interactive Data File (the cover page XBRL tags are embedded in the Inline XBRL document).

​

​

​

​

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

​

​	​	​	​
​	​ ACCENDRA HEALTH, INC. ​
​	​
November 2, 2026	​	/s/ Jonathan A. Leon
​	​	​	Jonathan A. Leon
​	​	​	Executive Vice President and Chief Financial Officer

​

Exhibit 99.1

Accendra Health Announces Extension of $150 Million Receivables Sale Program To 2029

​

​

Richmond, VA – November 2, 2026 – Accendra Health, Inc. (NYSE: ACH) (the “Company”) today announced that it executed an amendment to its Receivables Purchase Agreement (the “Receivables Sale Program”) on October 29, 2026. The amendment, among other things, extends the Scheduled Termination Date of the facility to October 2029, and the $150 million size of the Receivables Sale Program is unchanged.

​

“We are pleased to have worked with our banking partner to extend the Receivables Sale Program until October of 2029. The facility size remains unchanged, further ensuring the Company’s liquidity strength, and we believe that this continued partnership demonstrates the strength of our accounts receivable portfolio and processes,” said Jonathan Leon, EVP and Chief Financial Officer of Accendra Health, Inc.  

​

Safe Harbor

This release is intended to be disclosure through methods reasonably designed to provide broad, non-exclusionary distribution to the public in compliance with the SEC’s Fair Disclosure Regulation. This release contains certain “forward looking” statements made pursuant to the Safe Harbor provisions of the Private Securities Litigation Reform Act of 1995. These statements include, but are not limited to, the statements in this release regarding our future prospects and performance, including our expectations with respect to our financial performance, our 2026 financial results, our expectations regarding the performance of our business following the completion of the sale of the Products & Healthcare Services business, our cost saving initiatives, future indebtedness and growth, industry trends, as well as statements related to our expectations regarding the performance of our business, including our ability to address macro and market conditions. Forward-looking statements involve known and unknown risks and uncertainties that may cause our actual results in future periods to differ materially from those projected or contemplated in the forward-looking statements. Investors should refer to the Company’s Annual Report on Form 10-K for the year ended December 31, 2025, filed with the SEC on February 20, 2026, including the section captioned “Item 1A. Risk Factors,” as applicable, and subsequent quarterly reports on Form 10-Q and current reports on Form 8-K filed with or furnished to the SEC, for a discussion of certain known risk factors that could cause the Company’s actual results to differ materially from its current estimates. These filings are available at www.accendrahealth.com. Given these risks and uncertainties, the Company can give no assurance that any forward-looking statements will, in fact, transpire and, therefore, cautions investors not to place undue reliance on them. The Company specifically disclaims any obligation to update or revise any forward-looking statements, whether as a result of new information, future developments or otherwise.

​

About Accendra Health

Accendra Health, Inc. (NYSE: ACH) is a leading nationwide provider of products, technology, and services that support health beyond the hospital for millions of people each year. We connect patients, providers, and insurers, delivering innovative solutions that help promote better health outcomes and improve quality of life for people living with chronic, complex health conditions. Backed by the industry-leading expertise of our Apria and Byram brands, Accendra Health is reimagining the future of home-based care. To learn more about our broad portfolio of essentials for diabetes, sleep health, wound care, respiratory care, urology, and ostomy, visit www.accendrahealth.com.

​

​

ACH-CORP

​

ACH-IR

​

Contacts

Investors
Will Parrish
Vice President, Corporate Development & Investor Relations
Investor.Relations@accendra.com

1

​

Media
Darla Turner
media@accendra.com

2

Filing Exhibits & Attachments

5 documents

Press Releases

• EX-99.1 EX-99.1 8.5 KB

Other Documents

• EX-101 EX-101.SCH 3.4 KB
• EX-101 EX-101.DEF 2.8 KB
• EX-101 EX-101.LAB 19.7 KB
• EX-101 EX-101.PRE 10.8 KB